Oramed Pharmaceuticals Inc. Overview
Pro stress-test →Oramed Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering oral drug delivery solutions for therapeutic proteins through its proprietary Protein Oral Delivery (POD™) technology. The company's flagship program is ORMD-0801, an oral insulin capsule in Phase III development for diabetes treatment, which addresses a significant unmet need by replacing injectable insulin with oral administration.
Strategic Profile
Pro stress-test →Oramed leverages its platform technology to address multiple indications beyond diabetes, including COVID-19 vaccines through licensing agreements with Oravax Medical. The company has shifted toward a hybrid R&D and investment strategy, monetizing its technology through joint ventures (notably OraTech with Chinese partner HTIT) and strategic financial investments, including significant equity positions in complementary companies that have generated substantial unrealized gains.
Competitive Landscape
Pro stress-test →Oramed competes in the broader diabetes therapeutics and oral biologics delivery space against established pharmaceutical companies and emerging biotech firms developing alternative delivery mechanisms. Key competition includes conventional insulin manufacturers (Novo Nordisk, Eli Lilly, Sanofi) and other oral delivery platform companies. Oramed's differentiation lies in its POD™ technology platform's ability to protect protein integrity through the gastrointestinal tract, a significant technical barrier to competition.
Industry Context
Oramed Pharmaceuticals Inc. operates in Biopharmaceuticals / Pharmaceutical Drug Development.
Key facts
Founded: 2002 · Headquarters: New York, United States · Employees: Not disclosed · Revenue: Minimal/Pre-commercial · Market cap: $90-100M